Sign in

ONVO on NASDAQ

Organovo

Logo: Organovo, Public domain, via Wikimedia Commons5

Medical laboratory and research company

Organovo Holdings, Inc. is an early-stage medical laboratory and research company which designs and develops functional, three dimensional human tissue (also known as 3D bioprinting technology) for medical research and therapeutic applications. Organovo was established in 2007 and is headquartered in San Diego, California. The company uses its internally developed NovoGen MMX Bioprinter for 3D bioprinting.3 Its shares trade on NASDAQ under the symbol ONVO.1 Wikipedia text CC BY-SA 4.0

Price unavailable

Last updated Oct 21, 2026.

Overview

2007Founded1

Compare with another stock.

  • TickerONVO on NASDAQ1
  • Industrybiotechnology1
  • HeadquartersSan Diego1
  • Websitewww.organovo.com
  • Incorporated inDE6
  • Business address5871 Oberlin Drive, Suite 150, San Diego, Ca 921216
  • Legal formCorporation4
  • LEI5299006J43FG1K827P444
  • StatusActive4
  • LEI statusLapsed (not renewed)4
  • Registered addressc/o CORPORATION SERVICE COMPANY, 251 LITTLE FALLS DRIVE, 19808 Wilmington, United States4
  • Registered withDivision of Corporations, Department of State, 51015954

See how the biggest companies compare on our leaderboards

Organovo Holdings, Inc. is an early-stage medical laboratory and research company which designs and develops functional, three dimensional human tissue (also known as 3D bioprinting technology) for medical research and therapeutic applications. Organovo was established in 2007 and is headquartered in San Diego, California. The company uses its internally developed NovoGen MMX Bioprinter for 3D bioprinting.3

Products and brands

The company bioprints and markets human tissues as a means of accelerating the preclinical drug testing and discovery process, enabling treatments to be created more quickly and at lower cost, and without immediate risks to living test subjects. Organovo has long-term expectations that this technology could be suitable for surgical therapy and transplantation. Organovo also partners with biopharmaceutical companies and academic medical centers to design, build, and validate more predictive in vitro tissues for disease modeling and toxicology. The living test tissues provide researchers the opportunity to test drugs before administering the drug to a living person; this bridges the gap between preclinical testing and clinical trials.

In 2015, Organovo signed an agreement to provide processes and technology to produce 3D printed human skin to L'Oreal for use in testing the safety and efficacy of cosmetic products.

In February 2025, Eli Lilly purchased Organovo's FXR program for $10 Million.

From Wikipedia’s article on Organovo, shared under CC BY-SA 4.0.7

Timeline

  1. 2007Founded Founded1

SEC filer profile

How Organovo is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGAROrganovo, Inc.2
  • CIK0001530838
  • Employer ID (EIN)26-02039742
  • Incorporated inDelaware2
  • Fiscal year endsDecember 312
  • Business address5871 Oberlin Drive, Suite 150, San Diego, CA 921212
  • Phone(858) 550-99932
  • On EDGAR sinceSep 22, 20112
  • Filings3 in all: D (2), D/A (1)2

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7